Status:
COMPLETED
Pioglitazone and Losartan Provides Additional Renoprotection
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Type 2 Diabetes
Diabetic Nephropathy
Eligibility:
All Genders
32-75 years
Phase:
NA
Brief Summary
Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with...
Eligibility Criteria
Inclusion
- Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
- 2h plasma glucose level of 7.5-13 mmol/L
- serum creatinine values between 190 and 660umol/L
- Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is \>150mg
- Informed consent
Exclusion
- Type1 diabetes or nondiabetic renal disease
- abnormal liver function
- heart dysfunction
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00364988
Start Date
January 1 2005
End Date
January 1 2006
Last Update
October 27 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.